Surge in use of Pfizer's COVID antiviral Paxlovid since May
Joe Raedle



New data from HHS shows that around 2.8M doses of Pfizer's (NYSE:PFE) COVID-19 antiviral Paxlovid were administered from Dec. 17, 2021-July 17, 2022. About 5.2M courses were ordered by states over that period.
The data indicates a significant increase in Paxlovid (nirmatrelvir and ritonavir) use since mid-May when a total of ~832K courses were administered.

The second-most administered COVID-19 therapeutic given to date is Merck's (NYSE:MRK) Lagevrio (molnupiravir), with 448K courses to date. Through May, 251K were administered.
About 385K doses of AstraZeneca's (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab) have been administered to date, along with ~323K doses of Eli Lilly's (NYSE:LLY) bebtelovimab.
In late June, Pfizer (PFE) asked the U.S. FDA for full approval of Paxlovid.